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Uterine leiomyomata (UL), the most prevalent pelvic tumors in women of reproductive age, pose a major public health problem given
their high frequency, associated morbidities, and most common indication for hysterectomies. A genetic component to UL predisposi-
tion is supported by analyses of ethnic predisposition, twin studies, and familial aggregation. A genome-wide SNP linkage panel was
genotyped and analyzed in 261 white UL-affected sister-pair families from the Finding Genes for Fibroids study. Two significant linkage
regions were detected in 10p11 (LOD ¼ 4.15) and 3p21 (LOD ¼ 3.73), and five additional linkage regions were identified with LOD
scores > 2.00 in 2q37, 5p13, 11p15, 12q14, and 17q25. Genome-wide association studies were performed in two independent cohorts
of white women, and a meta-analysis was conducted. One SNP (rs4247357) was identified with a p value (p ¼ 3.053 108) that reached
genome-wide significance (odds ratio ¼ 1.299). The candidate SNP is under a linkage peak and in a block of linkage disequilibrium in
17q25.3, which spans fatty acid synthase (FASN), coiled-coil-domain-containing 57 (CCDC57), and solute-carrier family 16, member
3 (SLC16A3). By tissue microarray immunohistochemistry, we found elevated (3-fold) FAS levels in UL-affected tissue compared to
matched myometrial tissue. FAS transcripts and/or protein levels are upregulated in various neoplasms and implicated in tumor cell
survival. FASN represents the initial UL risk allele identified in white women by a genome-wide, unbiased approach and opens a path
to management and potential therapeutic intervention.Introduction
Uterine leiomyomata (UL), commonly known as fibroids,
are benign tumors of the uterine myometrium. They repre-
sent the most prevalent pelvic tumors in women and are
found in more than 75% of women of reproductive age.1
Approximately 20%–25% of women with UL exhibit
symptoms including menorrhagia, infertility, pelvic pain,
and a range of complications during pregnancy.2 The
leading cause for hysterectomy in the United States, UL
account for >30% of all hysterectomies and >40% of
hysterectomies among women aged 45–64 years.3 Annual
health-care costs of UL are estimated at over two billion
dollars, most of which is associated with hysterectomies.4
Although UL pose a major public health problem, little is
known about the molecular basis for these tumors, and
treatment options are limited.
Genes involved in UL have been discovered by cytoge-
netic analysis. Approximately 40% of UL have a non-
random cytogenetic aberration, and several subgroups
are recognized and include t(12;14)(q14-15;q23-24), del(7)
(q22q32), trisomy 12, rearrangements involving 6p21 and
10q22, and deletions of 1p and 3q.5,6 Cytogenetic abnor-1Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; 2
and Women’s Hospital, Boston, MA 02115, USA; 3Department of Pathology,
Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA;
Mayo Medical School, Rochester, MN 55902, USA; 6Department of Human G
Angeles, Los Angeles, CA 90095, USA; 7Queensland Institute of Medical Rese
Military and Veterans’ Health, Herston 4006, Australia; 9WellcomeTrustCentre
University of Oxford, Oxford OX3 7BN, UK; 10Department of Psychiatry, W
11Division of Preventive Medicine, Brigham and Women’s Hospital, Boston
*Correspondence: cmorton@partners.org
http://dx.doi.org/10.1016/j.ajhg.2012.08.009. 2012 by The American Societ
The Americmalities have been correlated with tumor size, location,
and histology, which indicates that genetic events play a
fundamental role in UL biology.5,7,8 Cytogenetic heteroge-
neity of UL underlies phenotypic differences and supports
involvement of different pathways in tumor development.
Several factors predispose women to developing UL. Age,
obesity, parity, and race have all been associated with
prevalence of UL. Black women are disproportionately
affected by UL9—the incidence and prevalence rates for
these women are at least three times greater than those
for white women even after other known risk factors
are controlled.10 Further, analyses of twin studies and
familial aggregation indicate a genetic component to UL
predisposition; first-degree relatives of affected women
have a 2.5-fold higher risk of developing UL, and monozy-
gotic twins’ concordance for UL diagnosis is almost twice
that of dizygotic twins.11,12 Similarly, a study of a Finnish
cohort found that monozygotic twins’ concordance for
being hospitalized for UL was twice that of dizygotic
twins.13 These findings support a genetic predisposition
to developing UL, but no genome-wide study of UL in
white women has been reported. Several candidate-gene
association studies have been performed with limitedDepartment of Obstetrics, Gynecology, and Reproductive Biology, Brigham
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success, although variants in the 50 UTR of HMGA2 (MIM
600698), a gene involved in recurrent cytogenetic aberra-
tions of UL and known to play a primary role,14 have
been associated with UL diagnosis in a cohort of white
sister pairs.15 Finding additional pathogenetic sequences
that predispose women to UL will provide insight into
tumor development and could lead to screening strategies
or improved management and therapy.Subjects and Methods
Finding Genes for Fibroid Linkage Analysis
Sister pairs affected by UL were recruited for the ‘‘Finding Genes
for Fibroids’’ (FGFF) study. Approximately 385 sister pairs con-
sented to this project. Both sisters in each pair had medical-
record-confirmed UL, provided a blood sample, and completed
a questionnaire on clinical, reproductive, sexual, and family
history relating to UL. Other family members of the sisters also
contributed samples and completed questionnaires. Study partici-
pants were recruited under an institutional-review-board (IRB)
protocol approved by the Partners HealthCare System Human
Research Committee. DNA was isolated with a Puregene Blood
Kit (Gentra, Minneapolis, MN), and the DNA, pedigree informa-
tion, and UL affection status were provided to the genotyping
core at The Center for Inherited Disease Research at Johns Hopkins
University. A whole-genome SNP linkage scan was performed with
Illumina’s Human Linkage-12 Genotyping BeadChip (San Diego,
CA). In addition to 14 SNP markers, two families affected by
multiple Mendelian inconsistencies were excluded because of
low-quality genotype calls.
Linkage analysis was performed with Genehunter software with
samples from self-reported white sister pairs and family members,
which composed 261 families for a total of 1,103 individuals. The
minor allele frequency (MAF) of each SNP was calculated with the
genotype information from one sister in each family. SNPs were
prunedwith PLINK software16 on the basis of an r2 of 0.2, resulting
in a total of 4,196 SNPs for the final analysis. Sibling-pair analysis
was carried out with UL status as the phenotype, and significant
linkage with UL was defined as a LOD score greater than 3.6.
Despite particular interest in recruitment of black women, the
FGFF study has not yet reached an appropriate number of sister
pairs for this important analysis.Women’s Genome Health Study Association Study
Study participants were recruited under an IRB protocol approved
by the Partners HealthCare System Human Research Committee.
The Women’s Genome Health Study (WGHS)17 is a prospective
cohort of female North American health-care professionals repre-
senting Women’s Health Study (WHS) participants who provided
a blood sample at baseline and consent for blood-based analyses.
Participants in theWHSwere 45 years of age or older at enrollment
and free of cardiovascular disease, cancer, or other major chronic
illness. Additional information related to health and lifestyle was
collected by questionnaires throughout the WHS trial and by
continual observational follow up. WHS participants were asked
whether they had ever been diagnosed with UL, their age at diag-
nosis, whether their mother or sister had ever been diagnosedwith
UL, and their history of hysterectomy.
Genotyping in the WGHS sample was performed with the
HumanHap300 Duo ‘‘þ’’ chips or the combination of the Human-622 The American Journal of Human Genetics 91, 621–628, OctoberHap300Duo and iSelect chips (Illumina, San Diego, CA) according
to the Infinium II protocol. In either case, the custom SNP content
was the same; these custom SNPs were chosen without regard for
MAF for saturating candidate genes for cardiovascular disease, as
well as for increasing coverage of SNPs with known or suspected
biological function, e.g., disease association, nonsynonymous
changes, substitutions at splice sites, etc. For quality control, all
samples were required to have successful genotyping with Bead-
Studio v.3.3 software (Illumina) for at least 98% of the SNPs. A
subset of 23,294 individuals was identified to have self-reported
European ancestry, verified on the basis of multidimensional
scaling analysis of identity by state with the use of 1,443 ancestry
informative markers in PLINK v.1.06.16 The final data set of these
individuals included SNPs with a MAF > 1%, successful genotyp-
ing in 90% of subjects, and deviations not exceeding p ¼ 106
from Hardy-Weinberg equilibrium. Among the final 23,294 indi-
viduals of verified European ancestry, genotypes for a total of
2,608,509 SNPs were imputed from the experimental genotypes
and linkage disequilibrium (LD) relationships implicit in the
HapMap r.22 CEU (Utah residents with ancestry from northern
and western Europe from the CEPH collection) samples. Imputed
SNPs were used for defining the LD region surrounding association
signals found with genotyped SNPs.
UL status, age at diagnosis, mother or sister UL status, and
history of hysterectomy were ascertained by recall in the 2009
WGHS questionnaire. UL cases and controls from the WGHS
were stratified on the basis of these four variables for identifying
women most and least likely to have a genetic basis for UL. Any
participant who answered ‘‘not sure’’ for UL status or mother or
sister UL status was excluded from the analysis. Participants who
reported an age of UL diagnosis to be under 20 years or over
70 years were also excluded. Cases included womenwho answered
‘‘yes’’ for UL status and ‘‘yes’’ for mother or sister UL status and
who either had an age of diagnosis under 40 years or had a hyster-
ectomy. Controls included women who answered ‘‘no’’ to UL
status and ‘‘no’’ to mother or sister UL status and who had not
had a hysterectomy. Women not qualifying for either of these
groups were excluded from the analysis. After stratification, there
were 746 cases and 4,487 controls. Association analysis was per-
formed on the set of 339,187 genotyped SNPs in PLINK with the
standard case-control test, and p values less than 5 3 108 were
considered significant.
Australian Cohort Association Study
Individuals composing the cohort from the Queensland Institute
of Medical Research (QIMR) were women who had given consent
and who had been genotyped previously on Illumina’s 317K,
370K, or 610K SNP platforms as part of a larger collection of
genome-wide association studies conducted at the QIMR.18,19
Case samples (n ¼ 484) were selected from among women origi-
nally recruited into a study of genetic factors underlying endome-
triosis20 and a twin study of gynecological health.21 For both
studies, women completed questionnaires on various aspects of
reproductive health, and cases answered ‘‘yes’’ to the ‘‘uterine
fibroids’’ option of the question ‘‘Have you ever had any of the
following conditions?’’ Controls (n¼ 610) were taken from among
twin pairs from the gynecological health study in which both
sisters answered ‘‘no’’ to the question on uterine fibroids (one
sample per twin pair). A standard case-control association analysis
was performed on the set of 269,629 SNPs genotyped in common
between all samples and passing all quality-control metrics in
PLINK.16 Approval for the studies was granted by the Human5, 2012
Linkage 
Peak Band 
Highest 
LOD Position (bp) 
2q37.1 2.41 179605032-239157621 
3p21.31 3.73 169614-76307730 
5p13.3 2.13 2956307-74194893 
10p11.21 4.15 9632527-72985946 
11p15.5 2.53 278505-7282771 
12q14.1 2.62 38583007-76110787 
17q25.3 2.15 64478082-78138144 
Figure 1. Summary of FGFF Sibling-Pair
Linkage Analysis by Chromosome
Two peaks have significant (>3.6) LOD
scores, and five peaks have suggestive
(>2.0) LOD scores. Linkage-peak bound-
aries and the highest LOD score found
under each peak are defined in the inserted
table.Research Ethics Committee at the QIMR and the Australian Twin
Registry. All gene annotations and base-pair positions are derived
from the human genome sequence hg18 (NCBI build 36.1).
Demographics
Demographics of the FGFF, WGHS, and Australian cohorts were
considered with a focus on variables most relevant to UL diag-
nosis. In the WGHS and Australian cohorts, cases had a slightly
higher bodymass index (BMI) and lower stature than did controls,
although the differences were not significant in the WGHS popu-
lation (defined as a p > 0.05) (Table S1, available online). Previous
studies also reported a correlation between UL diagnosis and
a higher BMI.22,23 WGHS and Australian cases also had a younger
age at menarche, which could be expected because UL are
hormone-dependent neoplasms and because a younger age at
menarche is associated with longer reproductive years and addi-
tional years of hormone exposure. Lastly, although Australian
cases were not selected on the basis of a history of hysterectomy,
UL cases had a very significant increase in hysterectomy preva-
lence, reflecting the fact that UL are the leading cause for this
surgery. Overall, demographics of the WGHS and Australian
cohorts were unremarkable and confirmed previously reported
UL associations.
FAS Immunohistochemistry
Fatty-acid synthase (FAS [MIM 600212]) levels in UL and myome-
trium tissue were analyzed by immunohistochemistry of tissue
microarrays (TMAs) consisting of tissue sections from 200 women:
36 myometrium samples and 337 UL samples. The TMA includes
matched paraffin-embedded formalin-fixed myometrium and UL
samples from 33 women. Two TMAs were constructed with
sections from different areas of the same tissue. DNA correspond-
ing to 106 tissue sections was isolated and used for genotyping
rs4247357 in CCDC57. Immunostaining was performed on both
TMAs with the primary monoclonal antibody against FAS (Trans-
duction Laboratories, Lexington, KY) at a 1:100 dilution and with
hematoxylin as a counterstain. Each core was evaluated for the
ratio of stain to counterstain for accounting for variable cellularity
in tissue sections. The average stain-to-counterstain ratio wasThe American Journal of Human Gdetermined and compared across myome-
trium and UL samples and also across
samples with the major and minor allele
of rs4247357. Errors bars and statistical
differences were determined by standard
error.
mRNA-Expression Analysis
by Microarray
RNAwas isolated frommyometrium tissue
and 28 UL from 14 women. Gene-expres-
sion levels were analyzed with the Affyme-trix GeneChip system U133 plus 2.0. DNA was also extracted and
used for genotyping rs4247357 in CCDC57. Gene-expression
levels were compared between women with the major and minor
allele of rs4247357.
Targeted mRNA-Expression Analysis by
Quantitative PCR
RNA was isolated from myometrium tissue and 20 tumors from
12 women, 6 of whom had the major allele of rs4247357 and
6 of whom had the minor allele. cDNA was synthesized and
used in quantitative PCR (qPCR) assessments of FASN, CCDC57,
SLC16A3 (MIM 603877), DUS1L, CSNK1D (MIM 600864), and
NARF (MIM 605349). Gene products were normalized to the
internal reference gene, GAPDH, and averaged normalized
ratios were compared across myometrium and UL samples and
across women with the major and minor allele of rs4247357.
Error bars and statistical differences were determined by standard
error.
Results
Linkage Study
Linkage analysis with the FGFF population revealed two
peaks with highly significant (>3.6) genome-wide LOD
scores and five peaks with suggestive (>2.0) LOD scores
(Figure 1). The highest LOD scores found were at 10p11
(LOD¼ 4.15) and 3p21 (LOD¼ 3.73). Both linkage regions
are around 35 Mb and contain hundreds of genes. Of note,
HMGA2 resides within the linkage region at 12q14 and has
a suggestive LOD score of 2.62 (Figure S1).
Association Analyses and Meta-analysis
Genome-wide association studies were undertaken with
two independent cohorts of white women—the WGHS
cohort and an Australian cohort. Analysis of the WGHS
cohort revealed 45 SNPs with p values less than 104
(Table S2). Although none of the p values from thisenetics 91, 621–628, October 5, 2012 623
Table 1. The Top SNP from Meta-analysis Results of WGHS and Australian Cohorts
SNP Locus Position (Gene) Cohort MAF OR (95% CI) p Value
rs4247357 17q25.3 WGHS 0.467 1.307 (1.170–1.459) 1.95 3 106
77,760,277 Australian 0.432 1.282 (1.079–1.523) 4.49 3 103
(CCDC57) meta-analysis  1.299 (1.184–1.426) 3.05 3 108
The following abbreviations are used: MAF, minor allele frequency; OR, odds ratio; and CI, confidence interval.analysis are considered significant for identifying
a genome-wide association, the quantile-quantile plot of
the results provides evidence that there are more SNPs
with small p values than are expected by chance
(Figure S2A). In the Australian analysis, 25 SNPs were iden-
tified with p values less than 104, and the quantile-quan-
tile plot reveals a small increase in low p values, although it
is less striking than the WGHS results (Table S3 and
Figure S2B). A meta-analysis was performed on the set of
344,655 genotyped SNPs from the WGHS and Australian
cohorts with the use of an inverse-variance weighted
method in METAL. One SNP, rs4247357, reached
genome-wide significance and is considered significantly
associated with UL status (Table 1). Five additional SNPs
in the same location on chromosome 17 were identified
with p values less than 106. The quantile-quantile plot
of the meta-analysis results clearly shows that this group
of SNPs has lower p values than what would be expected
under the null hypothesis (Figure 2). The candidate SNPs
on chromosome 17 are located in a large LD block, which
contains three genes, fatty-acid synthase (FASN), coiled-
coil-domain-containing 57 (CCDC57), and solute carrier
family 16, member 3 (SLC16A3) (Figure 3 and Figure S3).Figure 2. Quantile-Quantile Plot of Meta-analysis Results
The p values observed in the study are compared to p values ex-
pected under the null hypothesis. Top SNPs in the 17q25.3 region
are circled in green.
624 The American Journal of Human Genetics 91, 621–628, OctoberInterestingly, this LD block lies under the FGFF linkage
peak at 17q25 (Figure S4).
FAS Protein Levels
Little is known about CCDC57 or SLC16A3; however, FAS
has been associated with several cancers and is often upre-
gulated in cancer tissue.24 In order to investigate this
finding in UL, we stained UL and myometrial tissue
with a FAS antibody. FAS immunostaining revealed that
FAS levels in UL were three times higher than those in
matched, normal myometrium tissue (Figure 4). An
increase in UL FAS was seen in 25 out of 33 (~76%)
matched samples (Figure S5). Stratifying matched samples
by rs4247357 genotype showed an increase in FAS levels in
myometrium tissue and UL with the minor (effect) allele
compared to those with the major allele. Increased expres-
sion inmyometrium samples with theminor allele was not
substantial, but the increase in UL with the minor allele
was about 2-fold (Figure 5A). When all UL samples were
combined, the same pattern emerged, but the increase in
FAS in UL with the minor allele was about 50% higher
than in UL with the major allele (Figure 5B). Interestingly,
in the matched analysis, FAS levels in both myometrium
and UL samples heterozygous for major and minor alleles
were between those of samples homozygous for either
the major or minor alleles.
mRNA Expression
Analysis of mRNA-expression levels in myometrium tissue
and UL by microarray of genes under the linkage peak on
chromosome 17 revealed no genes with significant differ-
ential expression between women with the major (n ¼ 3)
and minor alleles (n ¼ 6) of rs4247357. FASN, CCDC57,
and SLC16A3 were found not to be expressed at a detect-
able level in the myometrium and UL samples analyzed.
However, a more comprehensive analysis of 54,000 probes
across the genome revealed that several genes were signif-
icantly more upregulated and downregulated in UL with
theminor allele than in ULwith themajor allele (Table S4).
Targeted mRNA-expression analysis by qPCR detected
no substantial expression differences in matched myome-
trium and UL samples for FASN, CCDC57, SLC16A3,
and three genes (DUS1L, CSNK1D, and NARF) located
directly nearby but outside of the candidate LD block
(Figure S6A). Expression of FASN, CCDC57, and SLC16A3
was slightly higher in thematched UL samples, but expres-
sion of DUS1L and NARF was also higher in the matched5, 2012
Figure 3. Candidate Region on Chromo-
some 17 Contains Significantly Associated
Markers
The p values for WGHS genotyped SNPs
are indicated by diamonds, the p values
for WGHS imputed SNPs are indicated
by circles, and the p values for SNPs
included in themeta-analysis are indicated
by triangles.UL samples, and the variation between samples was rela-
tively large. It is unclear whether this expression difference
has biological significance; however, it is clear that mRNA
expression of FASN betweenmyometrium andmatched UL
samples is not concordant with FAS levels because the
same samples were used in both studies. This finding is
not surprising because the correlation between mRNA
and protein levels can be poor—some studies find that
only 40% of variation in protein expression can be ex-
plained by mRNA expression.25 Also, expression of all six
genes was higher in myometrium tissue and UL with the
major allele than in those with the minor allele (Figures
S6B and S6C). Similarly, it is unclear whether this differ-
ence is of relevance because it is relatively small and is
observed for every gene analyzed and because the variation
between samples is relatively large.The American Journal of Human GeDiscussion
The FGFF linkage study provides
evidence of a genetic contribution to
UL development, as seen by two
significant linkage peaks and several
other suggestive peaks. Although
candidate genes have yet to be iden-
tified under five peaks, one gene
(HMGA2) prominently recognized in
UL biology is located under the peak
on 12q14. Translocations involvingHMGA2 are frequently found in UL tumors.14 Additionally,
a recent study using the FGFF population found a signifi-
cant association between UL status and a variant in the
50 UTR of HMGA2.15 The discovery of several linkage peaks
illustrates the genetic heterogeneity of these tumors and is
consistent with the hypothesis that a variety of genes and
pathways participate in UL development. Additionally,
a genome-wide association study in a Japanese cohort
found three loci (10q24.33, 22q13.1, and 11p15.5) signifi-
cantly associated with UL diagnosis.26 These loci are not
associated with UL in our cohorts of white women, and
our locus at 17q25.3 was not identified in the Japanese
study, supporting genetic heterogeneity in UL predisposi-
tion between ethnic groups.
Association analyses using the WGHS and Australian
cohorts might have identified more precisely the locusFigure 4. FAS levels in Myometrium
Tissue and UL from Matched Samples
Representative tissue cores are shown from
myometrium tissue (left) and UL (right). A
significant increase compared to myome-
trium was determined by a t test (*p ¼
0.004). The error bars were determined by
standard error.
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Figure 5. FAS Levels in Myometrium
Tissue and UL fromMatched Samples and
All Samples Stratified by the rs4247357
Genotype
Matched samples (A) and all samples
stratified by the rs4247357 genotype (B).
The error bars were determined by stan-
dard error.underlying the linkage signal on chromosome 17. Six SNPs
on chromosome 17 were in the top associated SNPs in the
WGHS analysis and proved to be significantly associated
with UL status after meta-analysis of the WGHS and
Australian cohorts. At this time, it is unknown whether
any of these markers are the causal SNP associated with
UL affection status or whether they are in LD with the
causal variant; however, these data show that the MAFs
of the candidate SNPs are significantly higher in women
with UL. The candidate SNPs are in LD across FASN,
CCDC57, and SLC16A3. SLC16A3 is a member of the
proton-linked monocarboxylate transporter family, which
facilitates transport of substrates across the plasma
membrane. CCDC57 contains a coiled-coil domain and
might function by binding DNA. SLC16A3 and CCDC57
are minimally characterized, making it difficult to conjec-
ture about their possible involvement in UL development.
None of these genes or proteins has been indicated in
disease, and our qPCR studies did not reveal any unusual626 The American Journal of Human Genetics 91, 621–628, October 5, 2012mRNA expression in UL. Conversely,
we found that FAS levels were much
higher inUL than inmatchedmyome-
trial tissue, as well as in myometrium
and UL from women with the minor
(effect) allele than in those from
women with the major allele. FAS
has been extensively characterized
and is the enzyme responsible for
de novo fatty-acid synthesis. It is
most highly expressed in hormone-
sensitive cells27 and has been found
to be regulated at both transcriptional
and posttranscriptional levels. Sterol-
regulatory-element-binding transcrip-
tion factor 1 (SREBP-1 [MIM 184756])
is the primary transcription factor of
FASN and is activated downstream of
growth-factor and hormone recep-
tors.28 FAS is stabilized by USP2a, an
isopeptidase that deubiquitinates and
prevents protein degradation. USP2a
is overexpressed in some prostate
tumors with high FAS expression29
and could explain discordant levels
of FASN mRNA and FAS levels in our
UL samples.
Upregulation of FAS has been
discovered in many cancers, in-cluding prostate, breast, and colon cancers.30–32 In some
cancers, upregulation of FAS is correlated with poor prog-
nosis, cancer progression, or specific tumor types.33 Inhib-
itors of FAS lead to growth arrest and apoptosis in cancer
cell lines and have relatively minor effects in correspond-
ing normal cells.34,35 Many studies have found a connec-
tion between FAS and the PI3K/Akt signaling pathway,
one of the most frequently dysregulated pathways in
human cancers.36,37 FAS inhibitors used in breast cancer
animal models and several xenograft models have resulted
in delayed development and slowed tumor progres-
sion.38,39 Knocking down FASN mRNA causes a host of
changes in gene expression and protein activity in the
cell,40 making it clear from these and many more studies
that the role of FAS in neoplasia is muchmore complicated
and probably more important than simply providing fatty
acids. Although it remains to be known how the minor
allele of the candidate LD block influences FASN and UL
development, upregulation of FAS in these UL samples
and the overwhelming evidence that FAS is a metabolic
oncogene make it a compelling candidate gene for UL
development, for which clinical trials with inhibitors
might be warranted.Supplemental Data
Supplemental Data include six figures and four tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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